Study Identifies GMPS as Driver of Pancreatic Ductal Adenocarcinoma via Suppression of Cellular Senescence

Researchers reported that GMPS drives pancreatic ductal adenocarcinoma progression by suppressing DNA damage and cellular senescence, indicating that targeting GMPS could provide a therapeutic pathway to induce senescence in aggressive cancers.

Researchers integrated DepMap and TCGA database data to screen 2,752 metabolic genes essential for pancreatic ductal adenocarcinoma (PDAC) proliferation and prognosis.

GMPS was identified as having the highest hazard ratio, and its high expression correlated with worse prognosis in 97 PDAC tissue samples and multiple cell lines.

Knockdown of GMPS in PDAC cell lines, organoids, and patient-derived xenograft (PDX) models reduced tumor growth and colony formation.

Mechanistically, GMPS knockdown triggered DNA damage (γH2AX⁺ cells), G1 phase arrest, activated the STING-TBK1 pathway, and induced cellular senescence (upregulation of IL6, MMP2, p21, and increased SA-β-gal staining).

PDAC is an aggressive malignancy with highly limited treatment targets, making the identification of metabolic drivers like GMPS highly valuable.

The study shows that metabolic rewiring can actively suppress cellular senescence to facilitate tumor growth, positioning GMPS as a novel therapeutic target and potential prognostic biomarker.

This finding underscores the dual nature of senescence biology in clinical translation: while longevity developers focus on clearing senescent cells (senolytics) to alleviate age-related diseases, oncology research often targets the induction of cellular senescence to arrest tumor growth.

The discovery may stimulate metabolic drug screening programs focused on GMPS inhibitors as pro-senescence cancer therapies.

Development and preclinical testing of selective GMPS inhibitors in pancreatic cancer models, both as monotherapies and in combination with immunotherapies.